Trial results

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity

NCT06972459 on ClinicalTrials.gov · last registry update 2026-07-29

Closed to new participants; the 800 already enrolled are still being followed. Due to report August 2027, alongside 39 other tracked readouts that quarter. Primary outcome, as filed: Percent Change from Baseline in Body Weight. Sponsors move these dates routinely; any movement since this site started watching is listed below. orforglipron is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status

ACTIVE_NOT_RECRUITING

Phase

P3

Drug

orforglipron

Foundayo

Sponsor

Eli Lilly and Company

Sponsor type

Industry

Enrollment

800

Started

2025-05-15

Primary completion

2027-08 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Percent Change from Baseline in Body Weight

Conditions studied

Obesity · Overweight

Every field above is taken directly from the registry record. See all detected changes across the class, or the orforglipron page for this molecule’s full trial and approval history.